	-		
September 21, 2001			

C1		. с		#	(
Sheet	I	ot	l		7

orm 1449*			Docket Number: G&C 129.23-US-U1 Application Number: 09/698,781				
. *	TION DISCLOSURE ST		PF			ICENTIER 1600/2900	
A	IN AN APPLICATION	OIPE	Filing Date: October 27, 2000 Group Art Unit: 1645 1642				<u> </u>
PIRE		•	. K		5R		贸
- 1	· · · · · · · · · · · · · · · · · · ·	OCT 0 2 200	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				क
20 ᡨ	19:	W -	U.S. PATENT DOCUMENTS		1		8
XAMINER	DOCUMENT NO	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF	12
INITIAL		(None				APPROPRIATE	8
							-
							_
			1				
							7
						-	1
							╣
							4
							7
					-		-
			<u> </u>				_
		l	FOREIGN PATENTS	I	T	[_
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	-
						YES NO	_
CO	WO 99/06550 🗸	02/11/99	PCT (p. 1, 4-12, 130-134, SEQ				
5R			ID NO: 311)		· ·		

							7
							\dashv
							_
	ОТНІ	ER DOCUME	NTS (Including Author, Title, Date, Pe	rtinent Pages,	Etc.)		_]
			The human cystein-rich secretory p				
5R	· ·	tribution of C	RISP-1, CRISP-2 and CRISP-3," 19	996, XP-000	997999, Eur. J.	Biochem. 236:827-	
1	836	1 "CC"	P20			- out-on-billo swith	-
1			P28, a novel matrix glycoprotein in estis-specific gene product and to a				
-			ers 380:246-250	Louent spen	counting give	p. 500m, 1770, A1	
			ic markers in localized prostate can	cer: From n	nicroscopes to	molecules," 1999,	1
	XP-0009	97993, Cance	and Metastasis Reviews, 17:429-43	7		•	_
			stic and Prognostic Markers for Hu	man Prostate	e Cancer," 1997	7, XP-000998020,	
		tate, 31:264-2			VD 0000700	· A	-
1			Markers for Prostate Cancer Metas	tasis," 1997,	XP-00099/980	, American Jounal	
		ogy, 150(5):1: chmar et alA	pril 12, 1996, GenBank Accession	No. X95240	+		┥.
	J. Teluciou						- i
	L. Kjeldsen, November 1, 2000, GenBank Accession No. NM_006061 L. Kjeldsen et al., March 4, 1996, GenBank Accession No. X94323						1
1							
	- 1 1 Clus	LII LL AI., INUV	cinder 1, 2000, Ochidana / iccession				

EXAMINER: 1 Pm	DATE CONSIDERED:	4/23/03				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in						
conformance and not considered. Include copy of this form for next communication to the Applicant.						

^{*}Substitute Disclosure Statement Form (PTO-1449)